Literature DB >> 34865694

Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL).

Archie Bleyer1.   

Abstract

Four categories of important factors improving outcome of young adults and older adolescents with acute lymphoblastic leukemia (ALL) are biologic type, clinical trials, pediatric vs. adult treatment regimen, and psychosocial challenges. Overall, the outcome of ALL in the age group has improved and beginning to catch up with that in children, as exemplified by CALGB 10403, a pediatric treatment regimen. Each is dependent for optimum development, however, on progress in the others. Without adequate psychosocial support and improvement, progress in clinical trials, translational research, and pediatric regimen application is impaired. Without clinical trials, advances in translational research, optimal pediatric regimen application and adequate psychosocial research are restricted. Overall, we have improved the outcome and outlook of ALL in AYAs, as exemplified by CALGB 10403, but we and our current and future patients still have a long way to go.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Clinical trials; Incidence peak; Pediatric treatment regimen; Psychosocial care; Young adults

Mesh:

Year:  2021        PMID: 34865694     DOI: 10.1016/j.beha.2021.101322

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  2 in total

1.  A Multicenter Cohort Study on Children Suffering from Acute Lymphoblastic Leukemia: Effects of Obesity on Mortality.

Authors:  Xiangwen Wang; Dan Mu; Anyang Geng; Anqi Zhao; Yiyuan Song
Journal:  Comput Math Methods Med       Date:  2022-07-05       Impact factor: 2.809

2.  Effect of Treatment in a Specialized Pediatric Hemato-Oncology Setting on 5-Year Survival in Acute Lymphoblastic Leukemia: A Quasi-Experimental Study.

Authors:  Margrietha van der Linde; Nikki van Leeuwen; Frank Eijkenaar; Anita W Rijneveld; Rob Pieters; Henrike E Karim-Kos
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.